Keywords: Molecular Imaging, Molecular Imaging
Motivation: Simultaneous enhancing MRI signals and effectively generating and activating immune cells is a significant challenge when using one contrast agent.
Goal(s): This work aims to develop nanoparticles of guiding tumor synergistic therapy using 1H/19F MRI while activating the STING pathway.
Approach: FMBI nanoparticles were designed for enhancement of 1H/19F MRI and activation of the immune system.
Results: FMBI nanoparticles responsively release Mn ions in the tumor microenvironment to enhance the signals of 1H/19F MRI and improve immune pathway activity and anti-tumor efficacy.
Impact: Our synthesized FMBI nanoparticles are a STING pathway-activatable contrast agent that can be used for 1H/19F MRI-guided tumor therapy with high efficacy, which shows promise for effective tumor immunotherapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords